NXTC — NextCure, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1661059 ·
Last close
$6.70
Market Cap
$30.68M
52W High
$15.74
52W Low
$1.55
ADV30
63,864
Next earnings
—
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -8,963,000 -6,846,000 9,700,000 8,728,000 4,197,000
Jun 2026 0 — -10,017,000 -14,892,000 22,620,000 15,260,000 10,471,000
Mar 2026 0 — -10,105,000 -9,796,000 37,977,000 15,167,000 11,261,000
Dec 2025 0 — -9,757,000 -9,436,000 50,183,000 25,982,000 15,240,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-42,790,000
Investing CF
$22,630,000
Financing CF
$21,564,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.18
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-467,514,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-38,842,000
Pretax Income TTM
$-40,970,000
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -57,616,000 -55,844,000 50,183,000 15,240,000 34,943,000 -49,613,000
Dec 2024 0 -57,206,000 -55,654,000 80,860,000 15,388,000 65,472,000 -40,805,000
Dec 2023 0 -67,637,000 -62,723,000 128,038,000 13,617,000 114,421,000 -52,974,000
Dec 2022 0 -75,909,000 -74,733,000 184,161,000 16,631,000 167,530,000 -53,886,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-42,748,000
OpCashFlow TTM
—
Assets (Latest)
$22,620,000
Forward EPS
$-5.89

Peers — same industry

TickerNameMarket CapLastDaily %
BCTX BriaCell Therapeutics Corp. $30.65M $3.51 —
RNTX Rein Therapeutics, Inc. $30.75M $0.36 —
NSRX Nasus Pharma Ltd $30.57M $2.61 —
RLFTY MindMaze Therapeutics Holding SA $30.24M $0.18 —
TELO Telomir Pharmaceuticals, Inc. $31.17M $0.42 —

News headlines (Yahoo Finance, 1h cache)

NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
2026-11-10 21:05 · Yahoo
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-06 20:01 · Yahoo
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
2026-07-14 12:00 · Yahoo
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
2026-05-04 11:05 · Yahoo
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
2026-04-21 14:15 · Yahoo
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
2026-03-31 20:05 · Yahoo
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
2026-04-07 12:05 · Yahoo
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
2026-06-01 12:00 · Yahoo
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
2026-06-04 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.